![conference banner](/images/conference-banner.jpeg)
Abstract
Previous clinical studies suggest that intravenous (IV) recombinant tissue plasminogen activator (rt-PA) benefits stroke patients regardless of the underlying etiology. In this study, we assessed the possible differences in response to IV rt-PA between cardioembolic stroke and other stroke subtypes. A total of 303 consecutive stroke ischemic patients (from January 2005 to April 2014) admitted to our Stroke Unit and treated with IV rt-PA were retrospectively reviewed. All patients were classified in two groups: Cardioembolic (CE) and Non-Cardioembolic (NCE). We analyzed a total of 303 patients. Thirty patients died in the first hours after fibrinolysis and no statistically significant differences were found in two groups (14 CE vs 18 N-CE). We observed a significant differences in clinical outcome in terms of symptoms ”improvement” (p<0.01 2) and symptoms” regression” (p<0.057 2) even if this last result did not reach statistical significance in CE patients respect to N-CE patients.
In conclusion, the intravenous fibrinolysis is more effective in CE group than in N-CE regarding symptoms ”improvement” and the PFO-Stroke patients treated with fibrinolysis have better outcome than other patients and they have high rate of symptoms” regression”. Moreover the main predictor of good outcomes were younger age and milder stroke severity on hospital admission.
Keywords: rt-PA, cardioembolic stroke, non-cardioembolic stroke, PFO-Stroke patients, symptoms improvement, symptoms regression.
Current Neurovascular Research
Title:Effect of Cardioembolic Etiology on Intravenous Thrombolysis Efficacy for Acute Ischemic Stroke
Volume: 13 Issue: 3
Author(s): Sabrina Anticoli, Maria Cristina Bravi, Giovanni Perillo, Antonio Siniscalchi, Claudio Pozzessere, Francesca Romana Pezzella, Piero Tanzi, Luca Gallelli and Domenico Cartoni
Affiliation:
Keywords: rt-PA, cardioembolic stroke, non-cardioembolic stroke, PFO-Stroke patients, symptoms improvement, symptoms regression.
Abstract: Previous clinical studies suggest that intravenous (IV) recombinant tissue plasminogen activator (rt-PA) benefits stroke patients regardless of the underlying etiology. In this study, we assessed the possible differences in response to IV rt-PA between cardioembolic stroke and other stroke subtypes. A total of 303 consecutive stroke ischemic patients (from January 2005 to April 2014) admitted to our Stroke Unit and treated with IV rt-PA were retrospectively reviewed. All patients were classified in two groups: Cardioembolic (CE) and Non-Cardioembolic (NCE). We analyzed a total of 303 patients. Thirty patients died in the first hours after fibrinolysis and no statistically significant differences were found in two groups (14 CE vs 18 N-CE). We observed a significant differences in clinical outcome in terms of symptoms ”improvement” (p<0.01 2) and symptoms” regression” (p<0.057 2) even if this last result did not reach statistical significance in CE patients respect to N-CE patients.
In conclusion, the intravenous fibrinolysis is more effective in CE group than in N-CE regarding symptoms ”improvement” and the PFO-Stroke patients treated with fibrinolysis have better outcome than other patients and they have high rate of symptoms” regression”. Moreover the main predictor of good outcomes were younger age and milder stroke severity on hospital admission.
Export Options
About this article
Cite this article as:
Anticoli Sabrina, Bravi Cristina Maria, Perillo Giovanni, Siniscalchi Antonio, Pozzessere Claudio, Pezzella Romana Francesca, Tanzi Piero, Gallelli Luca and Cartoni Domenico, Effect of Cardioembolic Etiology on Intravenous Thrombolysis Efficacy for Acute Ischemic Stroke, Current Neurovascular Research 2016; 13 (3) . https://dx.doi.org/10.2174/1567202613666160506125426
DOI https://dx.doi.org/10.2174/1567202613666160506125426 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms of β -lactam Resistance Among Pseudomonas aeruginosa
Current Pharmaceutical Design Dendrimers and Dendritic Polymers as Anti-infective Agents: New Antimicrobial Strategies for Therapeutic Drugs
Anti-Infective Agents in Medicinal Chemistry Malignant Hypertension: A Rare Problem or is it Underdiagnosed?
Current Vascular Pharmacology Cardiovascular Disease in Antiphospholipid Syndrome
Current Vascular Pharmacology Cardiac Workup of Ischemic Stroke
Current Cardiology Reviews Oral Inflammation and Bacteremia: Implications for Chronic and Acute Systemic Diseases Involving Major Organs
Cardiovascular & Hematological Disorders-Drug Targets Current Developments in Therapeutic and Diagnostic Strategies for Q Fever: Glimpses of Patent Analysis
Recent Patents on Anti-Infective Drug Discovery Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Evolution and Analysis of Heterogeneity in the Clinical Expression of Aortic Diseases Similar to Marfan’s Syndrome: Challenge and Art in Clinical Diagnosis
Current Rheumatology Reviews Human Immunodeficiency Virus (HIV) and Stroke: Targets for Intervention
Infectious Disorders - Drug Targets Prosthetic Valve Endocarditis: Diagnostic Approach and Treatment Options
Cardiovascular & Hematological Disorders-Drug Targets Vaccine Therapy for P. acnes-Associated Diseases
Infectious Disorders - Drug Targets Intracellular Life of Coxiella burnetii in Macrophages: Insight into Q Fever Immunopathology
Current Immunology Reviews (Discontinued) Susceptibility of Intracellular Coxiella burnetii to Antimicrobial Peptides in Mouse Fibroblast Cells
Protein & Peptide Letters <i>Corynebacterium Striatum</i>, an Emerging Nosocomial Pathogen: Case Reports
Infectious Disorders - Drug Targets Structure Based Virtual Screening for the Identification of Potential Inhibitors for Penicillin Binding Protein 2B of the Resistant 5204 Strain of <i>Streptococcus pneumoniae</i>
Current Bioinformatics Virtual Screening for the Development of New Effective Compounds Against Staphylococcus aureus
Current Medicinal Chemistry Antibacterial Combination of Oleoresin from Copaifera multijuga Hayne and Biogenic Silver Nanoparticles Towards Streptococcus agalactiae
Current Pharmaceutical Biotechnology Evaluation and Management of Asymptomatic Bradyarrhythmias
Current Cardiology Reviews Bacteriophage and Peptidoglycan Degrading Enzymes with Antimicrobial Applications
Recent Patents on Biotechnology